Santersus Advances NucleoCapture® into Multinational Pivotal Study in Sepsis
Up to 350-patient randomized NUC-CAP study to assess safety, organ support and organ dysfunction in sepsis; Axcellant appointed global CRO to support execution ZURICH, SWITZERLAND, October 22, 2026 /EINPresswire.com/ -- Santersus AG (“Santersus” or the …